Patents by Inventor Stephanie Decker

Stephanie Decker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE
    Publication number: 20200353055
    Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
    Type: Application
    Filed: July 29, 2020
    Publication date: November 12, 2020
    Inventors: Petr Kuzma, Stephanie Decker
  • DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE
    Publication number: 20190388500
    Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.
    Type: Application
    Filed: September 9, 2019
    Publication date: December 26, 2019
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Stephanie Decker
  • Implant device release agents and methods of using same
    Patent number: 9120249
    Abstract: Medical implant devices are prepared from a polymeric material and a release agent, where the device is a molded, reservoir implant, and the release agent has a molecular weight (MW) of at least 1000. The release agent may be a non-ionic surfactant such as Brij 35, polyoxyetheylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS, and a mixture of any two or more thereof. Hydrated implants may have a surface area of about 500 mm2 or greater.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: September 1, 2015
    Assignee: ENDO PHARMACEUTICALS SOLUTIONS INC.
    Inventors: Petr Kuzma, Stephanie Decker, Harry Quandt
  • Controlled release formulations of octreotide
    Patent number: 8507432
    Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: August 13, 2013
    Assignee: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Stephanie Decker
  • CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE
    Publication number: 20100317579
    Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
    Type: Application
    Filed: June 11, 2010
    Publication date: December 16, 2010
    Inventors: Petr KUZMA, Stephanie Decker
  • CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE
    Publication number: 20090087470
    Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
    Type: Application
    Filed: September 29, 2008
    Publication date: April 2, 2009
    Inventors: Petr KUZMA, Stephanie Decker
  • IMPLANT DEVICE RELEASE AGENTS AND METHODS OF USING SAME
    Publication number: 20080311170
    Abstract: Medical implant devices are prepared from a polymeric material and a release agent, where the device is a molded, reservoir implant, and the release agent has a molecular weight (MW) of at least 1000. The release agent may be a non-ionic surfactant such as Brij 35, polyoxyetheylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS, and a mixture of any two or more thereof. Hydrated implants may have a surface area of about 500 mm2 or greater.
    Type: Application
    Filed: April 25, 2008
    Publication date: December 18, 2008
    Inventors: Petr Kuzma, Stephanie Decker, Harry Quandt
  • Controlled release formulations of octreotide
    Patent number: 7452868
    Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: November 18, 2008
    Assignee: Indevus Pharmaceuticals, Inc.
    Inventors: Petr Kuzma, Stephanie Decker
  • Controlled release formulations of octreotide
    Publication number: 20060204540
    Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
    Type: Application
    Filed: March 10, 2006
    Publication date: September 14, 2006
    Inventors: Petr Kuzma, Stephanie Decker